Stockscreener 앱 받기
3.00
1.35%
0.04
시간 외 거래:
3.00
전일 마감가:
$2.96
열려 있는:
$3
하루 거래량:
1.98M
Relative Volume:
0.60
시가총액:
$327.58M
수익:
-
순이익/손실:
$-209.38M
주가수익비율:
-1.5985
EPS:
-1.8768
순현금흐름:
$-179.81M
1주 성능:
+2.74%
1개월 성능:
-14.77%
6개월 성능:
-8.81%
1년 성능:
-52.15%
1일 변동 폭
$2.95
$3.06
1주일 범위
$2.87
$3.165
52주 변동 폭
$2.19
$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.00 | 323.21M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-08-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
JP Morgan Downgrades Rocket Pharmaceuticals (RCKT) - MSN
Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote, News & History - Benzinga
RCKT Should I Buy - Intellectia AI
Rocket Pharmaceuticals (RCKT) CEO logs small stock sale to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) counsel sells small stake to cover RSU taxes - Stock Titan
Rocket Pharmaceuticals (RCKT) officer sells 384 shares to cover RSU tax withholding - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) files Form 144 to sell 55,684 shares - Stock Titan
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting - Investing.com Canada
Rocket Pharmaceuticals shareholders approve board nominees and proposals at annual meeting By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals - TipRanks
Rocket Pharmaceuticals (RCKT) investors approve directors, pay and option exchange - Stock Titan
Rocket Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going? - Insider Monkey
Proposed resale of 2,409 Common shares by RCKT filer (Form 144) - Stock Titan
Director resale notice — RCKT (NASDAQ: RCKT) lists 384 shares from vesting - Stock Titan
662-Share Rule 144 Notice for RCKT (NASDAQ: RCKT) - Stock Titan
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Rocket Pharmaceuticals, Inc.Common Stock (NQ: RCKT - The Chronicle-Journal
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M - Insider Monkey
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Rocket Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
RCKT Stock Price, Quote & Chart | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock - Investing.com UK
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock By Investing.com - Investing.com South Africa
Rocket Pharma general counsel Wilson sells $12,119 in stock - Investing.com UK
Rocket Pharma general counsel Wilson sells $12,119 in stock By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,837 in stock By Investing.com - Investing.com Australia
Rocket Pharmaceuticals VP John Militello sells $3,083 in stock - Investing.com
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax withholding - Stock Titan
Rocket Pharma (RCKT) CEO sells shares to cover RSU tax obligations - Stock Titan
Rocket Pharmaceuticals (RCKT) insider sells 855 shares for tax withholding - Stock Titan
RCKT (NASDAQ) Rule 144: Director sales listed; 3,361 vested shares - Stock Titan
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
RCKT (NASDAQ: RCKT) files Form 144 for 855 vested shares - Stock Titan
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Lifesci Capital Analysts Raise Earnings Estimates for RCKT - MarketBeat
TradingKey - TradingKey
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock - Investing.com India
Rocket Pharmaceuticals (RCKT) insider sale covers RSU tax obligations - Stock Titan
Rocket Pharmaceuticals pursues gene therapy advances at Heart Failure 26 to accelerate early diagnosis - Traders Union
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus - The Globe and Mail
Number of shareholders of Rocket Pharmaceuticals, Inc. – GETTEX:9IP1 - TradingView
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rocket Pharmaceuticals Inc 주식 (RCKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wilson Martin | General Counsel |
May 19 '26 |
Sale |
3.01 |
662 |
1,995 |
677,977 |
| Militello John | See Remarks |
May 19 '26 |
Sale |
3.01 |
384 |
1,157 |
89,780 |
0.98%
0.12%
자본화:
|
볼륨(24시간):